Results 131 to 140 of about 5,304 (170)

Alternative oncogenic drivers and sensitivity to BTK inhibition in CRISPR/Cas gene-edited human DLBCL cell models. [PDF]

open access: yesBlood Neoplasia
Eken JA   +10 more
europepmc   +1 more source

Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma. [PDF]

open access: yesAm J Hematol
Smith SD   +12 more
europepmc   +1 more source

Cardiovascular Toxicity of BTK Inhibitors: A Patient-Centered Framework for Risk Stratification and Management. [PDF]

open access: yesJ Clin Med
Tedeschi A   +17 more
europepmc   +1 more source

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update. [PDF]

open access: yesIntern Med J
McKeague S   +27 more
europepmc   +1 more source

Bruton Tyrosine Kinase Inhibitor-Associated Pericardial Events by Agent and Generation.

open access: yesJAMA Netw Open
Serra VSB   +16 more
europepmc   +1 more source

BTK dynamics and function are differentially influenced by distinct covalent inhibitor warhead chemistries

open access: yes
Joseph RE   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy